Transition from Evogam to Hizentra AU SCIg products
In May 2022, the National Blood Authority (NBA) announced that five domestically produced plasma products are undergoing transition in 2023 and 2024.
From 2 August 2023, patients on EVOGAM subcutaneous immunoglobulin (SCIg) product will transition to HIZENTRA AU, if they have not already transitioned. The timing of when each patient will transition will be determined by their treating team and it is anticipated that most patients will be transitioned by October 2023.
HIZENTRA AU will continue to be manufactured from Australia’s plasma and is approved by the Therapeutics Goods Administration (TGA) in accordance with usual high standards of safety and quality.
This NBA handout provides details and timing for the transition.
This news item was issued on 26 July 2023 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.
